| Followers | 202 |
| Posts | 25627 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Monday, September 20, 2021 10:56:59 AM
Anders you are confusing many things to get to the conclusion you are stuck on. Advent is the facilities manager, and they are already qualified, which is a part of the process. They have a GMP certification for their OWN facility already, in London. That license does not however carry over to Sawston.
Contract manufacturing is a common thing. Turnkey factories are a common thing though in this case NWBO already has the facility. The facilities operator no doubt is a very important element of the certification process, it is just something that can be transferred with the right personnel and/or organization substituting, and Advent is basically providing the Human Resources and expertise in this context.
You are stuck on the idea that the two are inextricably linked, that much value from NWBO is somehow in Advent, and you seem not to understand the flexibility that contract manufacturing brings to a manufacturing operation. The flexibility is a critical point. And just as easily as it could be Advent, it could be Cognate, or CRL, or another contract manufacturer slotted in there. Getting the initial processes set-up, since Advent comes out of Cognate, there is no doubt it is probably the best option other than Cognate, but then after that, likely many other possible providers could be slotted in, or it can be set-up so that ultimately NWBO takes over the contracts of key employees, and gets qualified to operate its own plant.
None of this is brain surgery. It’s just common practice. And the PR’s do not suggest by any stretch of the imagination that anything is different here, nor are they necessarily likely to change the typical reality.
Sorry.
Contract manufacturing is a common thing. Turnkey factories are a common thing though in this case NWBO already has the facility. The facilities operator no doubt is a very important element of the certification process, it is just something that can be transferred with the right personnel and/or organization substituting, and Advent is basically providing the Human Resources and expertise in this context.
You are stuck on the idea that the two are inextricably linked, that much value from NWBO is somehow in Advent, and you seem not to understand the flexibility that contract manufacturing brings to a manufacturing operation. The flexibility is a critical point. And just as easily as it could be Advent, it could be Cognate, or CRL, or another contract manufacturer slotted in there. Getting the initial processes set-up, since Advent comes out of Cognate, there is no doubt it is probably the best option other than Cognate, but then after that, likely many other possible providers could be slotted in, or it can be set-up so that ultimately NWBO takes over the contracts of key employees, and gets qualified to operate its own plant.
None of this is brain surgery. It’s just common practice. And the PR’s do not suggest by any stretch of the imagination that anything is different here, nor are they necessarily likely to change the typical reality.
Sorry.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
